Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give their informed consent to participate
• People aged 18 or older
• People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through a tissue or cell sample
• People who are currently receiving hormone therapy to lower testosterone (either through medication or surgical removal of the testicles), with testosterone levels at or below a certain low level at the time of screening
• People whose prostate cancer has spread to other parts of the body, confirmed by bone scan and/or CT scan
• People whose cancer has continued to grow or spread despite hormone therapy, shown by rising PSA levels over time and/or new or worsening areas on scans
• People with a PSA level of 2 ng/mL or higher
• People with a general health status rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out daily activities with no more than moderate limitation) (confirm with trial site)
• People whose cancer-related pain is stable and well-controlled, with no urgent need for radiation treatment
• People with an estimated life expectancy of at least 12 months
• People who have stored prostate cancer tissue available to share, or who are willing to have a new tumour biopsy taken
• People whose blood counts, liver function, kidney function, and other organ measures fall within acceptable ranges as determined by blood tests (confirm with trial site)
• People who have stopped any other prostate cancer treatments (except bone-protecting medications such as denosumab or bisphosphonates) at least 3 weeks before joining the trial
• People who are able to swallow the trial medication and follow the trial requirements

Who may not be able to join:

• People with a serious medical or psychiatric condition that the trial doctor believes could interfere with participation
• People who have been diagnosed with or treated for another type of cancer (other than certain skin cancers, a specific type of bladder cancer, or carcinoma in situ that has been fully removed) within the past 2 years
• People with known or suspected cancer that has spread to the brain or the lining around the brain or spinal cord
• People whose prostate cancer has a specific cell type known as small-cell or neuroendocrine (confirm with trial site)
• People who have had radiation treatment to the prostate tumour itself within 3 weeks before the screening visit
• People who have had radiation or radioactive therapy to treat cancer spread (metastases) within 3 weeks before screening, unless it was given only to relieve pain
• People with a history of uncontrolled seizures, if they and their doctor are considering a specific trial medication called enzalutamide
• People with unstable heart conditions, including certain types of irregular heartbeat or significant heart failure
• People with a known HIV infection, or active hepatitis B or C infection
• People with a known gut or digestive condition that could affect how the trial medication is absorbed
• People who have previously been treated with certain hormone-blocking medications, including abiraterone, apalutamide, darolutamide, enzalutamide, or ketoconazole (note: prior treatment with docetaxel for earlier-stage prostate cancer is allowed)
• People with any other condition or situation that the trial doctor believes would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.